Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings bioAffinity Technologies, Inc.: Strengths and Weaknesses

Weaknesses: bioAffinity Technologies, Inc.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Rating Financials

bioAffinity Technologies, Inc. SectorUnited States

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

bioAffinity Technologies, Inc. SectorUnited States

Global Valuation

-

Enterprise value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

bioAffinity Technologies, Inc. SectorUnited States

Consensus

-

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

-

Analysts' recommendations evolution (4 months)

-

Analysts' target price

-

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings

Rating Business Predictability

bioAffinity Technologies, Inc. SectorUnited States

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

-

Rating Revisions

bioAffinity Technologies, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
7.64M - - - - - -
13.02B -
AA
- -
9.87B
A
6.05B
A
-
5.82B
BBB
4.54B - - - - - - -
4.28B
BBB
4.23B -
2.89B
CCC
-
2.83B -
BBB
- -
Average 5.35B
A
Weighted average by Cap.
A
  1. Stock Market
  2. Equities
  3. BIAF Stock
  4. Ratings bioAffinity Technologies, Inc.